International Journal of Drug Policy
Volume 19, Issue 5 , Pages 401-409 , October 2008

Pleasure and discipline in the uses of Ritalin

  • Helen Keane

      Affiliations

    • Corresponding Author InformationTel.: +61 2 6125 2734; fax: +61 2 6125 4490.

Received 19 April 2007 ,Revised 4 July 2007 ,Accepted 8 August 2007.

References 

  1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed.. Washington, DC: American Psychiatric Association; 2000;
  2. Barkley RA. Attention-Deficit Hyperactivity Disorder: A handbook for diagnosis and treatment. 2nd ed.. New York and London: The Guildford Press; 1998;
  3. Breggin PR, Breggin G. The hazards of treating “attention-deficit/hyperactivity disorder” with methylphenidate (Ritalin). The Journal of College Student Psychotherapy. 1995;10(2):55–72
  4. Brock D. Enhancements of human function: Some distinctions for policymakers. In:  Parens E editors. Enhancing human traits: Ethical and social implications. Washington, DC: Georgetown University Press; 1998;p. 30–48
  5. Children, Youth and Women's Health Service. (2006) ADD and ADHD—What are they? Retrieved 17 December 2006 from http://www.cyh.com/HealthTopics/HealthTopicDetails.aspx?p=114&np=141&id=1644.
  6. Coveney J, Bunton R. In pursuit of the study of pleasure: Implications for health research and practice. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine. 2003;7(2):161–179
  7. Davis, J. (2000). Ritalin—Prescriptions don’t seem to matter for some. WebMD Medical News. Retrieved 15 December 2006 from http://www.webmd.com/content/article/35/1728_57356.htm.
  8. DeGrandpre R. Ritalin nation: Rapid-fire culture and the transformation of human consciousness. New York: W.W. Norton; 2000;
  9. Derrida J. The rhetoric of drugs. An interview. Differences: A Journal of Feminist Cultural Studies. 1993;5(1):2–25
  10. Diller L. Running on Ritalin. New York: Bantam; 1998;
  11. Duff C. Drug use as a practice of the self: Is there any place for an ethics of moderation in contemporary drug policy?. International Journal of Drug Policy. 2004;15:385–393
  12. Elliott C. Better than well: American medicine meets the American dream. New York and London: W.W. Norton; 2003;
  13. Gomart E. Methadone: Six effects in search of a substance. Social Studies of Science. 2002;32(1):93–135
  14. Halasz G. ‘Smartening up’ or ‘dumbing down’? A look behind the symptoms, at overprescribing and reconceptualising ADHD. In:  Halasz G, et al. editor. Cries unheard: A new look at Attention Deficit Hyperactivity Disorder. Alton: Common Ground; 2002;p. 75–91
  15. Honos-Webb L. The gift of ADHD. Oakland: New Harbinger; 2005;
  16. Keane H. What's wrong with addiction?. Melbourne: Melbourne University Press; 2002;
  17. Klein RG, Wender P. The role of methylphenidate in psychiatry. Archives of General Psychiatry. 1995;52(6):429–433
  18. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: A review of available evidence and relevance to the ADHD patient. Journal of Clinical Psychiatry. 2003;64(11):14–18
  19. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects. Pharmacology, Biochemistry and Behaviour. 2001;68:611–627
  20. Koob GF, Barak C, Hyytia P, Markou A, Parsons LH, Roberts AJ, et al. Neurobiology of drug addiction. In:  Glantz MD,  Hartel CR editor. Drug abuse: Origins and interventions. Washington, DC: American Psychological Association; 1999;p. 161–190
  21. Krautkramer C. Beyond creativity: ADHD drug therapy as a moral damper on a child's future success. The American Journal of Bioethics. 2005;5(3):52–53
  22. Landry M. Understanding drugs of abuse. Washington, DC: American Psychiatric Press; 1994;
  23. Law J. After ANT: Complexity, naming and topology. In:  Law J,  Hassard J editor. Actor Network Theory and after. Oxford: Blackwell; 1999;p. 2–15
  24. Leshner A. Addiction is a brain disease and it matters. Science. 1997;278(5335):45–46
  25. Leshner A. Foreword. In:  Glantz MD,  Hartel CR editor. Drug abuse: Origins and interventions. Washington, DC: American Psychological Association; 1999;p. 161–190
  26. Mash EJ, Wolfe DA. Abnormal child psychology. 2nd ed.. Belmont, CA: Wadsworth; 2002;
  27. Miller T, Leger MC. A very childish moral panic: Ritalin. Journal of Medical Humanities. 2003;24(1/2):9–33
  28. Moore, D. (2006). Where did the pleasure go in drug discourses? Paper presented at Dangerous Consumptions IV colloquium, held at Australian National University in Canberra, Australia.
  29. Muller J. The well-tempered learner: Self regulation, pedagogical models and teacher education policy. Comparative Education. 1998;34(2):177–193
  30. National Institute on Drug Abuse. (2006). NIDA infofacts: Methylphenidate (Ritalin). Retrieved 15 December 2006 from http://www.nida.nih.gov/pdf/infofacts/Ritalin06.pdf.
  31. Office of National Drug Control Policy. (2000). Drug policy information clearinghouse fact sheet: Methadone. Retrieved 15 December 2006 from http://www.whitehousedrugpolicy.gov.
  32. O’Malley P, Mugford S. The demand for intoxicating commodities: Implications for the ‘War on Drugs’. Social Justice: A Journal of Crime, Conflict, and World Order. 1991;18:49–75
  33. Pandina RJ, Johnson VL. Why people use, abuse and become dependent on drugs: Progress toward a heuristic model. In:  Glantz MD,  Hartel CR editor. Drug abuse: Origins and interventions. Washington: American Psychological Association; 1999;p. 119–147
  34. Pfiffner L, Barkley R. Treatment of ADHD in school settings. In:  Barkley R editors. Attention-Deficit Hyperactivity Disorder: A handbook for diagnosis and treatment. 2nd ed.. New York and London: The Guildford Press; 1998;p. 458–490
  35. Roache JD, Grabowski J, Schmitz JM, Creson DL, Rhoades HM. Laboratory measures of methylphenidate effects in cocaine dependent patients receiving treatment. Journal of Clinical Psychopharmacology. 2000;20(1):61–68
  36. Robinson T, Berridge K. Addiction. Annual Review of Psychology. 2003;54:25–53
  37. Rose N. Inventing our selves: Psychology, power, and personhood. New York: Cambridge University Press; 1996;
  38. Royal Australasian College of Physicians. (2006). Medication management for Attention Deficit Hyperactivity Disorder: A brief guide for parents and non health professionals. Retrieved 15 December 2006 from http://www.racp.edu.au/hpu/paed/ADHD_statement.pdf.
  39. Safer DJ. Are stimulants overprescribed for youths with ADHD?. Annals of Clinical Psychiatry. 2000;12(1):55–62
  40. Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention-deficit/hyperactivity disorder. The Medical Journal of Australia. 2002;177(1):21–25
  41. Schultz W. Multiple reward signals in the brain. Nature Reviews Neuroscience. 2000;1:199–207
  42. Schultz D, Schultz S. A history of modern psychology. 4th ed.. San Diego: Harcourt Brace Jovanovich; 1987;
  43. Schwebel R. Saying no is not enough. New York: Newmarket Press; 1989;
  44. Shorter, E. (1997). The second biological psychiatry. In A history of psychiatry: From the era of the asylum to the age of Prozac (pp. 259–287). New York: John Wiley & Sons.
  45. Singh I. Bad boys, good mothers and the ‘miracle’ of Ritalin. Science in Context. 2002;15(4):577–603
  46. Singh I. Will the ‘real’ boy please behave: Dosing dilemmas for parents of boys with ADHD. The American Journal of Bioethics. 2005;5(3):34–47
  47. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry. 2002;63(12):3–9
  48. Stoops WW, Glaser PEA, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. Journal of Psychopharmacology. 2004;18(4):534–543
  49. Timimi S. ADHD is best understood as a cultural construct. British Journal of Psychiatry. 2004;184:8–9
  50. Titus J. Boy trouble: Rhetorical framing of boys’ underachievement. Discourse: Studies in the Cultural Politics of Education. 2004;25(2):145–169
  51. United States Department of Justice: Drug Enforcement Administration. (2006). Drugs and chemicals of concern: Methylphenidate. Retrieved 28 December 2006 from http://www.deadiversion.usdoj.gov/drugs_concern/methylphenidate.htm.
  52. valentine, k., & Fraser, S. (2005). Methadone and market corrections. Paper presented at Culture-Fix: The annual conference of the Cultural Studies Association of Australasia.
  53. Volkow ND, Ding Y, Fowler JS, Wang G, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry. 1995;52(6):456–463
  54. Werry J. Introduction. In:  Werry J,  Aman M editor. Practitioner's guide to psychoactive drugs for children and adolescents. 2nd ed.. New York and London: Plenum; 1999;p. 3–22
  55. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179–185
  56. Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. The New England Journal of Medicine. 1999;340(1):40–46

PII: S0955-3959(07)00153-3

doi: 10.1016/j.drugpo.2007.08.002

International Journal of Drug Policy
Volume 19, Issue 5 , Pages 401-409 , October 2008

Article Tools